EP0239631A4 - Apolipoproteines recombinantes et procedes. - Google Patents

Apolipoproteines recombinantes et procedes.

Info

Publication number
EP0239631A4
EP0239631A4 EP19860906545 EP86906545A EP0239631A4 EP 0239631 A4 EP0239631 A4 EP 0239631A4 EP 19860906545 EP19860906545 EP 19860906545 EP 86906545 A EP86906545 A EP 86906545A EP 0239631 A4 EP0239631 A4 EP 0239631A4
Authority
EP
European Patent Office
Prior art keywords
methods
recombinant apolipoproteins
apolipoproteins
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19860906545
Other languages
German (de)
English (en)
Other versions
EP0239631A1 (fr
Inventor
Andrew A Protter
Jean-Louis Vigne
Joanne B Mallory
Karen D Talmadge
John P Kane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotechnology Research Partners Ltd
Original Assignee
Biotechnology Research Partners Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotechnology Research Partners Ltd filed Critical Biotechnology Research Partners Ltd
Publication of EP0239631A1 publication Critical patent/EP0239631A1/fr
Publication of EP0239631A4 publication Critical patent/EP0239631A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP19860906545 1985-10-04 1986-10-02 Apolipoproteines recombinantes et procedes. Withdrawn EP0239631A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78441885A 1985-10-04 1985-10-04
US784418 1985-10-04
US80469285A 1985-12-04 1985-12-04
US804692 1985-12-04

Publications (2)

Publication Number Publication Date
EP0239631A1 EP0239631A1 (fr) 1987-10-07
EP0239631A4 true EP0239631A4 (fr) 1989-01-12

Family

ID=27120281

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860906545 Withdrawn EP0239631A4 (fr) 1985-10-04 1986-10-02 Apolipoproteines recombinantes et procedes.

Country Status (3)

Country Link
EP (1) EP0239631A4 (fr)
AU (1) AU6522486A (fr)
WO (1) WO1987002062A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
EP0347915A3 (fr) * 1988-06-23 1991-03-20 The Rockefeller University Méthode et agents inhibiteurs de la synthèse des lipoprotéines de basse densité
AU623698B2 (en) 1988-09-02 1992-05-21 Chiron Corporation Macrophage-derived inflammatory mediator (mip-2)
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
FR2666813A1 (fr) * 1990-09-18 1992-03-20 Rhone Poulenc Sante Procede microbiologique de preparation de l'apolipoproteine aiv humaine ou de derives de celle-ci.
CA2236982C (fr) * 1995-11-09 2010-07-27 The Government Of The United States Of America Represented By The Secretary Of The Department Of Health And Human Services Utilisation de la lecithine-cholesterol acyltransferase (lcat) dans le traitement de l'atherosclerose
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
MXPA02008616A (es) * 2000-03-03 2003-02-24 Smithkline Beecham Biolog Vacuna para el tratamiento de la arterosclerosis.
JP3944083B2 (ja) 2001-05-15 2007-07-11 株式会社Ｊｉｍｒｏ 高密度リポ蛋白質反応性ペプチド
US7759315B2 (en) 2005-03-09 2010-07-20 Csl Behring Ag Treatment of inflammatory conditions of the intestine
ATE555801T1 (de) 2007-03-01 2012-05-15 Csl Ltd Behandlung von endothelialer dysfunktion bei diabetes-patienten
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
JP5685529B2 (ja) 2008-06-13 2015-03-18 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダＰｒｏｙｅｃｔｏ Ｄｅ Ｂｉｏｍｅｄｉｃｉｎａ Ｃｉｍａ， Ｓ．Ｌ． 生物学的活性を有する化合物の投与のための複合体
JP5832898B2 (ja) 2008-11-10 2015-12-16 テクミラ ファーマシューティカルズ コーポレイションＴｅｋｍｉｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 治療薬を送達するための新規な脂質及び組成物
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
AU2010221419B2 (en) 2009-03-02 2015-10-01 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
CN102421900B (zh) 2009-03-12 2015-07-22 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因表达的脂质配制的组合物以及方法
NZ711583A (en) 2009-05-05 2017-03-31 Arbutus Biopharma Corp Lipid compositions
CN102625696B (zh) 2009-06-10 2015-06-03 阿尔尼拉姆医药品有限公司 改进的脂质制剂
EP2810643A3 (fr) 2009-08-14 2015-03-11 Alnylam Pharmaceuticals Inc. Compositions formulées de lipides et procédés d'inhibition de l'expression d'un gène à partir du virus Ebola
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
CA3044884A1 (fr) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions utilisees pour l'administration d'acides nucleiques
CA2784568A1 (fr) 2009-12-18 2011-06-23 Martin A. Maier Particules de lipide destinees a la distribution d'acides nucleiques
US9102938B2 (en) 2010-04-01 2015-08-11 Alnylam Pharmaceuticals, Inc. 2′ and 5′ modified monomers and oligonucleotides
WO2011133871A2 (fr) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Dérivés d'extrémité 5'
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133868A2 (fr) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Monomères de dinucléotide et oligonucléotides à conformation restreinte
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
AU2011261247B2 (en) 2010-06-03 2016-08-25 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
WO2012016188A2 (fr) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour l'administration d'agents actifs
WO2012064824A1 (fr) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Compositions à formulation lipidique et procédés d'inhibition de l'expression des gènes eg5 et vegf
DK2663548T3 (en) 2011-01-11 2017-07-24 Alnylam Pharmaceuticals Inc PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY
WO2013049328A1 (fr) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Lipides di-aliphatiques pegylés substitués
WO2014011908A1 (fr) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Mélanges d'apolipoprotéine
AU2015364508A1 (en) 2014-12-18 2017-07-06 Alnylam Pharmaceuticals, Inc. ReversirTM compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173280A1 (fr) * 1984-08-27 1986-03-05 Bio-Technology General Corporation Plasmides contenant des promoteurs lambda PL et site de restriction préparé pour le remplacement facile d'un site de liaison ribosomique, hôtes contenant les plasmides et méthodes correspondantes
WO1986004920A1 (fr) * 1985-02-13 1986-08-28 Biotechnology Research Partners, Limited Promoteur de la metallothioneine-ii humaine dans un systeme mammifere d'expression
WO1987002061A1 (fr) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Nouveaux systemes d'administration de medicaments a base de lipoproteines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2052516B (en) * 1979-06-01 1983-06-29 Searle & Co Plasmid vectors production and use thereof
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4579821A (en) * 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173280A1 (fr) * 1984-08-27 1986-03-05 Bio-Technology General Corporation Plasmides contenant des promoteurs lambda PL et site de restriction préparé pour le remplacement facile d'un site de liaison ribosomique, hôtes contenant les plasmides et méthodes correspondantes
WO1986004920A1 (fr) * 1985-02-13 1986-08-28 Biotechnology Research Partners, Limited Promoteur de la metallothioneine-ii humaine dans un systeme mammifere d'expression
WO1987002061A1 (fr) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Nouveaux systemes d'administration de medicaments a base de lipoproteines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 9, March 1987, pages 4241-4247, The American Society of Biological Chemists, Inc., Washington, DC, US; J. BEDNARZ MALLORY et al.: "Expression and characterization of human apolipoprotein A-I in Chinese hamster ovary cells" *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 25, no. 10, October 1982, pages 1115-1120, American Chemical Society, Washington, DC, US; R.E. COUNSELL et al.: "Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents" *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE, USA, vol. 83, March 1986, pages 1467-1471, Washington, DC, US; A.A. PROTTER et al.: "Isolation of a cDNA clone encoding the amino-terminal region of human apolipoprotein B" *
See also references of WO8702062A1 *

Also Published As

Publication number Publication date
WO1987002062A1 (fr) 1987-04-09
EP0239631A1 (fr) 1987-10-07
AU6522486A (en) 1987-04-24

Similar Documents

Publication Publication Date Title
EP0239631A4 (fr) Apolipoproteines recombinantes et procedes.
GB2183886B (en) Microbook and its associated bookgenerator unit
GB8530295D0 (en) Electromagnet arrangements
IL78519A (en) Recombinant inhibin
GR860078B (en) Spiro - dioxolanes - dithiolanes and oxothiolanes
DE3665956D1 (en) Electromagnet
GB8522200D0 (en) Cues
GB2184243B (en) Electromagnet arrangements
IL75919A0 (en) Recombinant factor viii-r
GB2184896B (en) Constructional components and arrangements
GB8505406D0 (en) Cues
IL79880A0 (en) Recombinant virus
ZA862848B (en) Recombinant inhibin
GB8500007D0 (en) Proteins
CS104986A1 (en) Optoelektronicke zarizeni pro kontrolu utkovych civek
IE862620L (en) Recombinant Apolipoproteins and Methods
IE851875L (en) Recombinant factor viii-r
GB8514728D0 (en) Modified polypeptide
GB8514730D0 (en) Modified polypeptide
IE851251L (en) Polypeptide
IE850674L (en) Isochromanes and oxepines.
IE850933L (en) 1-aminoalkylamino-4-aryloxypiperidines and related¹intermediates
GB8529452D0 (en) Recombinant plasmid
CS47885A1 (en) Zapojeni pro stabilisaci zisku zesilovacu b tridy
CS554085A1 (en) Zarizeni pro zjistovani rije u zvirat

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19870609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19890112

17Q First examination report despatched

Effective date: 19910425

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19941001

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KANE, JOHN, P.

Inventor name: PROTTER, ANDREW, A.

Inventor name: TALMADGE, KAREN, D.

Inventor name: MALLORY, JOANNE, B.

Inventor name: VIGNE, JEAN-LOUIS